Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


14.05.2018

2 BJU Int
1 BMC Cancer
1 BMC Urol
2 Br J Radiol
1 Cancer
1 Cancer Lett
1 Clin Imaging
4 Eur Urol
1 Int J Cancer
1 Int J Oncol
2 Int J Urol
1 J Magn Reson Imaging
2 J Nucl Med
2 J Urol
1 Magn Reson Imaging
1 N Engl J Med
1 Nat Rev Urol
1 Oncol Rep
4 Prostate
1 Semin Radiat Oncol
1 Urol Int
3 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. NEWTON RU, Jeffery E, Galvao DA, McIntyre C, et al
    Body composition, fatigue and exercise in patients with prostate cancer undergoing androgen deprivation therapy.
    BJU Int. 2018 May 11. doi: 10.1111/bju.14384.
    PubMed     Text format     Abstract available

  2. HOFMAN MS, Murphy DG, Williams SG, Nzenza T, et al
    A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    BJU Int. 2018 May 3. doi: 10.1111/bju.14374.
    PubMed     Text format     Abstract available


    BMC Cancer

  3. PARK JW, Koh DH, Jang WS, Cho KS, et al
    Predictors of adverse pathologic features after radical prostatectomy in low-risk prostate cancer.
    BMC Cancer. 2018;18:545.
    PubMed     Text format     Abstract available


    BMC Urol

  4. SATO H, Narita S, Tsuchiya N, Koizumi A, et al
    Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer.
    BMC Urol. 2018;18:32.
    PubMed     Text format     Abstract available


    Br J Radiol

  5. TIMON G, Ciardo D, Bazani A, Marvaso G, et al
    Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of phase II trial AIRC-IG-13218.
    Br J Radiol. 2018 May 11:20160725. doi: 10.1259/bjr.20160725.
    PubMed     Text format     Abstract available

  6. DI PAOLA V, Cybulski A, Belluardo S, Cavicchioli F, et al
    Evaluation of periprostatic neurovascular fibers before and after radical prostatectomy by means of 1.5 t mri diffusion tensor imaging.
    Br J Radiol. 2018 Feb 1:20170318. doi: 10.1259/bjr.20170318.
    PubMed     Text format     Abstract available


    Cancer

  7. BRYANT AK, D'Amico AV, Nguyen PL, Einck JP, et al
    Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
    Cancer. 2018 May 4. doi: 10.1002/cncr.31400.
    PubMed     Text format     Abstract available


    Cancer Lett

  8. ABISOYE-OGUNNIYAN A, Lin H, Ghebremedhin A, Salam A, et al
    Transcriptional Repressor Kaiso Promotes Epithelial to Mesenchymal Transition and Metastasis in Prostate Cancer through Direct Regulation of miR-200c.
    Cancer Lett. 2018 May 8. pii: S0304-3835(18)30319.
    PubMed     Text format     Abstract available


    Clin Imaging

  9. MENDEZ G, Foster BR, Li X, Shannon J, et al
    Endorectal MR imaging of prostate cancer: Evaluation of tumor capsular contact length as a sign of extracapsular extension.
    Clin Imaging. 2018;50:280-285.
    PubMed     Text format     Abstract available


    Eur Urol

  10. SANCHEZ-SALAS R, de la Rosette J, Polascik TJ, Carneiro A, et al
    Focal Therapy for Prostate Cancer: A More Vehement View of the Approach Could Translate into Real Benefits for Our Patients.
    Eur Urol. 2018 Apr 30. pii: S0302-2838(18)30320.
    PubMed     Text format     Abstract available

  11. KNIPPER S, Graefen M
    Palliative Radical Prostatectomy in Men with Metastatic Castration-resistant Prostate Cancer: Only When Your Back Is Against the Wall!
    Eur Urol. 2018 May 3. pii: S0302-2838(18)30334.
    PubMed     Text format    

  12. GONG J, Omlin A, Pal SK, Hsu J, et al
    Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer.
    Eur Urol. 2018 May 3. pii: S0302-2838(18)30330.
    PubMed     Text format    

  13. VICKERS A, Nordstrom T, Assel M, Lilja H, et al
    Re: Tobias Nordstrom, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Gronberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol 2015;68:139-46.
    Eur Urol. 2018 May 3. pii: S0302-2838(18)30333.
    PubMed     Text format    


    Int J Cancer

  14. HAGGSTROM C, Van Hemelrijck M, Garmo H, Robinson D, et al
    Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and type 2 diabetes mellitus.
    Int J Cancer. 2018 May 9. doi: 10.1002/ijc.31587.
    PubMed     Text format     Abstract available


    Int J Oncol

  15. QI Y, Zhao W, Li M, Shao M, et al
    High C-X-C motif chemokine 5 expression is associated with malignant phenotypes of prostate cancer cells via autocrine and paracrine pathways.
    Int J Oncol. 2018 Apr 30. doi: 10.3892/ijo.2018.4388.
    PubMed     Text format     Abstract available


    Int J Urol

  16. SAKAMOTO S
    Editorial Comment to Local treatment for metastatic prostate cancer: A systematic review.
    Int J Urol. 2018;25:403-404.
    PubMed     Text format    

  17. KIMURA T, Egawa S
    Epidemiology of prostate cancer in Asian countries.
    Int J Urol. 2018 May 8. doi: 10.1111/iju.13593.
    PubMed     Text format     Abstract available


    J Magn Reson Imaging

  18. SHIRADKAR R, Ghose S, Jambor I, Taimen P, et al
    Radiomic features from pretreatment biparametric MRI predict prostate cancer biochemical recurrence: Preliminary findings.
    J Magn Reson Imaging. 2018 May 7. doi: 10.1002/jmri.26178.
    PubMed     Text format     Abstract available


    J Nucl Med

  19. ELSCHOT M, Selnaes KM, Johansen H, Kruger-Stokke B, et al
    The Effect of Including Bone in DIXON-based Attenuation Correction for (18)F-fluciclovine PET/MRI of Prostate Cancer.
    J Nucl Med. 2018 May 4. pii: jnumed.118.208868. doi: 10.2967/jnumed.118.208868.
    PubMed     Text format     Abstract available

  20. DOUGHTON JA, Hofman MS, Eu P, Hicks RJ, et al
    A first-in-man study of (68)Ga-nanocolloid PET-CT sentinel lymph node imaging in prostate cancer demonstrates aberrant lymphatic drainage pathways.
    J Nucl Med. 2018 May 4. pii: jnumed.118.209171. doi: 10.2967/jnumed.118.209171.
    PubMed     Text format     Abstract available


    J Urol

  21. CRAWFORD ED, Schellhammer PF, McLeod DG, Moul JW, et al
    Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens.
    J Urol. 2018 May 3. pii: S0022-5347(18)43086-8. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  22. HOFBAUER SL, Kittner B, Maxeiner A, Heckmann R, et al
    Validation of PI-RADS version 2 for the detection of prostate cancer.
    J Urol. 2018 May 4. pii: S0022-5347(18)43099-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    Magn Reson Imaging

  23. LUTTJE MP, van Buuren LD, Luijten PR, van Vulpen M, et al
    Towards intrinsic R2* imaging in the prostate at 3 and 7tesla.
    Magn Reson Imaging. 2017 May 4. pii: S0730-725X(17)30087.
    PubMed     Text format     Abstract available


    N Engl J Med

  24. BARRY MJ, Rosenkrantz AB
    MRI-Targeted versus Ultrasonography-Guided Biopsy for Suspected Prostate Cancer.
    N Engl J Med. 2018;378:1835-1836.
    PubMed     Text format    


    Nat Rev Urol

  25. CHAU CH, Figg WD
    Revisiting 5alpha-reductase inhibitors and the risk of prostate cancer.
    Nat Rev Urol. 2018 May 8. pii: 10.1038/s41585-018-0018.
    PubMed     Text format    


    Oncol Rep

  26. LIU Z, Zhang H, Ding S, Qi S, et al
    betaKlotho inhibits androgen/androgen receptorassociated epithelialmesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling.
    Oncol Rep. 2018 Apr 25. doi: 10.3892/or.2018.6399.
    PubMed     Text format     Abstract available


    Prostate

  27. JARVIS C, Nelius T, Martinez-Marin D, Sennoune SR, et al
    Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Prostate. 2018 May 10. doi: 10.1002/pros.23647.
    PubMed     Text format     Abstract available

  28. MUNOZ-MORENO L, Schally AV, Prieto JC, Carmena MJ, et al
    Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
    Prostate. 2018 May 10. doi: 10.1002/pros.23648.
    PubMed     Text format     Abstract available

  29. TINAY I, Tan M, Gui B, Werner L, et al
    Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
    Prostate. 2018 May 10. doi: 10.1002/pros.23650.
    PubMed     Text format     Abstract available

  30. CHAKRAVARTHI BVSK, Goswami MT, Pathi SS, Dodson M, et al
    Expression and role of PAICS, a de novo purine biosynthetic gene in prostate cancer.
    Prostate. 2018;78:693-694.
    PubMed     Text format    


    Semin Radiat Oncol

  31. OJERHOLM E, Bekelman JE
    Finding Value for Protons: The Case of Prostate Cancer?
    Semin Radiat Oncol. 2018;28:131-137.
    PubMed     Text format     Abstract available


    Urol Int

  32. LUZZAGO S, Musi G, Catellani M, Russo A, et al
    Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
    Urol Int. 2018 May 7:1-9. doi: 10.1159/000488772.
    PubMed     Text format     Abstract available


    Urology

  33. MERRET C, Mannas M, Black PC, Zargar H, et al
    Magnet before the Needle: Commentary on MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis (PRECISION Trial).
    Urology. 2018 May 3. pii: S0090-4295(18)30393.
    PubMed     Text format    

  34. LI Q, Xiang F, Lin X, Grajo JR, et al
    The Role of Imaging in Prostate Cancer Care Pathway: Novel Approaches to Urologic Management Challenges Along Ten Imaging Touch Points.
    Urology. 2018 May 3. pii: S0090-4295(18)30395.
    PubMed     Text format     Abstract available

  35. ZHANG S, Li LH, Qiao HM, Yang X, et al
    Regulation of the Antioxidant-Response by MyoD Transcriptional Coactivator in Castration-Resistant Prostate Cancer Cells.
    Urology. 2018 May 3. pii: S0090-4295(18)30397.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: